STOCK TITAN

[Form 4] Axogen, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Form 4 snapshot: Axogen, Inc. (AXGN) disclosed that Director William P. Burke received 14,150 restricted stock units (RSUs) on 06/19/2025 as his annual board equity retainer, valued at approximately $150,000 on the grant date. The transaction is coded “A” (acquisition), confirming that no open-market trade occurred.

Each RSU converts to one share of common stock upon vesting, which is scheduled for 06/19/2026, the first anniversary of the grant. Until then the award remains a contingent right rather than outstanding shares.

Following the award Mr. Burke’s derivative holdings increased by 14,150 units, all held directly. The filing reports no dispositions, option exercises or sales, and does not affect the company’s share count or cash position. The grant aligns director compensation with long-term shareholder value and is routine under Axogen’s board compensation program.

Riepilogo del Modulo 4: Axogen, Inc. (AXGN) ha comunicato che il Direttore William P. Burke ha ricevuto 14.150 unità azionarie vincolate (RSU) il 19/06/2025 come compenso annuale in azioni per il consiglio di amministrazione, valutate circa 150.000 dollari alla data di assegnazione. La transazione è contrassegnata con la lettera “A” (acquisizione), confermando che non è avvenuta alcuna operazione sul mercato aperto.

Ogni RSU si converte in una azione ordinaria al momento della maturazione, prevista per il 19/06/2026, il primo anniversario dell’assegnazione. Fino ad allora, il premio rappresenta un diritto condizionato e non azioni effettive in circolazione.

A seguito dell’assegnazione, le partecipazioni derivate del Sig. Burke sono aumentate di 14.150 unità, tutte detenute direttamente. La documentazione segnala nessuna cessione, esercizio di opzioni o vendita, e non incide sul numero di azioni in circolazione né sulla liquidità della società. L’assegnazione è in linea con la politica di compenso del consiglio di amministrazione di Axogen e mira ad allineare la remunerazione dei direttori al valore a lungo termine per gli azionisti.

Resumen del Formulario 4: Axogen, Inc. (AXGN) informó que el Director William P. Burke recibió 14,150 unidades restringidas de acciones (RSUs) el 19/06/2025 como su retención anual en acciones del consejo, valoradas aproximadamente en $150,000 en la fecha de concesión. La transacción está codificada como “A” (adquisición), confirmando que no hubo operaciones en el mercado abierto.

Cada RSU se convierte en una acción común al momento del vencimiento, programado para el 19/06/2026, el primer aniversario de la concesión. Hasta entonces, el premio es un derecho contingente y no acciones en circulación.

Tras la concesión, las participaciones derivadas del Sr. Burke aumentaron en 14,150 unidades, todas mantenidas directamente. El informe no registra disposiciones, ejercicios de opciones ni ventas, y no afecta el recuento de acciones ni la posición de efectivo de la empresa. La concesión alinea la compensación de los directores con el valor a largo plazo para los accionistas y es rutinaria según el programa de compensación del consejo de Axogen.

Form 4 요약: Axogen, Inc. (AXGN)은 이사 William P. Burke가 2025년 6월 19일에 연간 이사회 주식 보수로 14,150개의 제한 주식 단위(RSU)를 받았으며, 부여일 기준 약 150,000달러 상당이라고 공개했습니다. 거래는 “A”(취득)로 코드화되어 공개 시장 거래가 없었음을 확인합니다.

각 RSU는 부여 1주년인 2026년 6월 19일에 베스팅되어 보통주 1주로 전환됩니다. 그때까지는 수상 권리가 조건부 권리로 남아 있으며, 발행 주식이 아닙니다.

수상 후 Burke 이사의 파생 보유량은 14,150 단위 증가했으며, 모두 직접 보유 중입니다. 신고서에는 처분, 옵션 행사 또는 매각 내역이 없으며, 회사의 주식 수나 현금 상태에 영향을 미치지 않습니다. 이번 수상은 이사 보수를 장기 주주 가치와 연계하며 Axogen 이사회 보수 프로그램에 따라 일상적으로 이루어집니다.

Résumé du formulaire 4 : Axogen, Inc. (AXGN) a révélé que le directeur William P. Burke a reçu 14 150 unités d’actions restreintes (RSU) le 19/06/2025 en tant que rémunération annuelle en actions du conseil d’administration, évaluées à environ 150 000 $ à la date d’attribution. La transaction est codée « A » (acquisition), confirmant qu’aucune transaction sur le marché ouvert n’a eu lieu.

Chaque RSU se convertit en une action ordinaire à la date d’acquisition, prévue pour le 19/06/2026, premier anniversaire de l’attribution. Jusque-là, la récompense reste un droit conditionnel et non des actions en circulation.

Suite à cette attribution, les avoirs dérivés de M. Burke ont augmenté de 14 150 unités, toutes détenues directement. Le dépôt ne signale aucune cession, exercice d’options ou vente, et n’affecte ni le nombre d’actions ni la trésorerie de la société. Cette attribution s’inscrit dans la politique de rémunération du conseil d’Axogen et vise à aligner la rémunération des administrateurs sur la création de valeur à long terme pour les actionnaires.

Formular 4 Zusammenfassung: Axogen, Inc. (AXGN) gab bekannt, dass Direktor William P. Burke am 19.06.2025 14.150 Restricted Stock Units (RSUs) als seine jährliche Vorstandsaktienvergütung erhielt, bewertet mit etwa 150.000 US-Dollar zum Zeitpunkt der Gewährung. Die Transaktion ist mit „A“ (Erwerb) gekennzeichnet, was bestätigt, dass kein Handel am offenen Markt stattfand.

Jede RSU wandelt sich bei der Vesting am 19.06.2026, dem ersten Jahrestag der Gewährung, in eine Stammaktie um. Bis dahin bleibt die Zuteilung ein bedingtes Recht und keine ausstehende Aktie.

Nach der Zuteilung erhöhte sich Burkes derivative Beteiligung um 14.150 Einheiten, die alle direkt gehalten werden. Die Meldung verzeichnet keine Veräußerungen, Optionsausübungen oder Verkäufe und beeinflusst weder die Aktienanzahl noch die Liquidität des Unternehmens. Die Zuteilung entspricht der Vorstandsvergütungspolitik von Axogen und dient der Ausrichtung der Vergütung an langfristigem Aktionärswert.

Positive
  • None.
Negative
  • None.

Insights

TL;DR — Standard RSU grant; neutral market impact, modest alignment signal.

The Form 4 simply records Axogen’s regular $150 k equity award to Director William Burke, translating into 14,150 RSUs that vest in one year. No shares were sold, no cash changed hands, and the award represents a fraction of AXGN’s ~40 m fully-diluted share base, so dilution is immaterial (<0.04%). As a non-cash expense the grant is already embedded in projected SBC. Investors should view the filing as routine governance housekeeping rather than a catalyst for the stock.

TL;DR — Governance-consistent director pay; no red flags detected.

Axogen uses annual RSU grants to encourage board retention and shareholder alignment. The one-year cliff vest is common for small-cap med-tech firms and avoids short-term trading incentives. Absence of a 10b5-1 checkbox indicates the award is not part of a scheduled sales plan, further reducing headline risk. Overall, the disclosure conforms to Section 16 requirements and presents a neutral corporate-governance signal.

Riepilogo del Modulo 4: Axogen, Inc. (AXGN) ha comunicato che il Direttore William P. Burke ha ricevuto 14.150 unità azionarie vincolate (RSU) il 19/06/2025 come compenso annuale in azioni per il consiglio di amministrazione, valutate circa 150.000 dollari alla data di assegnazione. La transazione è contrassegnata con la lettera “A” (acquisizione), confermando che non è avvenuta alcuna operazione sul mercato aperto.

Ogni RSU si converte in una azione ordinaria al momento della maturazione, prevista per il 19/06/2026, il primo anniversario dell’assegnazione. Fino ad allora, il premio rappresenta un diritto condizionato e non azioni effettive in circolazione.

A seguito dell’assegnazione, le partecipazioni derivate del Sig. Burke sono aumentate di 14.150 unità, tutte detenute direttamente. La documentazione segnala nessuna cessione, esercizio di opzioni o vendita, e non incide sul numero di azioni in circolazione né sulla liquidità della società. L’assegnazione è in linea con la politica di compenso del consiglio di amministrazione di Axogen e mira ad allineare la remunerazione dei direttori al valore a lungo termine per gli azionisti.

Resumen del Formulario 4: Axogen, Inc. (AXGN) informó que el Director William P. Burke recibió 14,150 unidades restringidas de acciones (RSUs) el 19/06/2025 como su retención anual en acciones del consejo, valoradas aproximadamente en $150,000 en la fecha de concesión. La transacción está codificada como “A” (adquisición), confirmando que no hubo operaciones en el mercado abierto.

Cada RSU se convierte en una acción común al momento del vencimiento, programado para el 19/06/2026, el primer aniversario de la concesión. Hasta entonces, el premio es un derecho contingente y no acciones en circulación.

Tras la concesión, las participaciones derivadas del Sr. Burke aumentaron en 14,150 unidades, todas mantenidas directamente. El informe no registra disposiciones, ejercicios de opciones ni ventas, y no afecta el recuento de acciones ni la posición de efectivo de la empresa. La concesión alinea la compensación de los directores con el valor a largo plazo para los accionistas y es rutinaria según el programa de compensación del consejo de Axogen.

Form 4 요약: Axogen, Inc. (AXGN)은 이사 William P. Burke가 2025년 6월 19일에 연간 이사회 주식 보수로 14,150개의 제한 주식 단위(RSU)를 받았으며, 부여일 기준 약 150,000달러 상당이라고 공개했습니다. 거래는 “A”(취득)로 코드화되어 공개 시장 거래가 없었음을 확인합니다.

각 RSU는 부여 1주년인 2026년 6월 19일에 베스팅되어 보통주 1주로 전환됩니다. 그때까지는 수상 권리가 조건부 권리로 남아 있으며, 발행 주식이 아닙니다.

수상 후 Burke 이사의 파생 보유량은 14,150 단위 증가했으며, 모두 직접 보유 중입니다. 신고서에는 처분, 옵션 행사 또는 매각 내역이 없으며, 회사의 주식 수나 현금 상태에 영향을 미치지 않습니다. 이번 수상은 이사 보수를 장기 주주 가치와 연계하며 Axogen 이사회 보수 프로그램에 따라 일상적으로 이루어집니다.

Résumé du formulaire 4 : Axogen, Inc. (AXGN) a révélé que le directeur William P. Burke a reçu 14 150 unités d’actions restreintes (RSU) le 19/06/2025 en tant que rémunération annuelle en actions du conseil d’administration, évaluées à environ 150 000 $ à la date d’attribution. La transaction est codée « A » (acquisition), confirmant qu’aucune transaction sur le marché ouvert n’a eu lieu.

Chaque RSU se convertit en une action ordinaire à la date d’acquisition, prévue pour le 19/06/2026, premier anniversaire de l’attribution. Jusque-là, la récompense reste un droit conditionnel et non des actions en circulation.

Suite à cette attribution, les avoirs dérivés de M. Burke ont augmenté de 14 150 unités, toutes détenues directement. Le dépôt ne signale aucune cession, exercice d’options ou vente, et n’affecte ni le nombre d’actions ni la trésorerie de la société. Cette attribution s’inscrit dans la politique de rémunération du conseil d’Axogen et vise à aligner la rémunération des administrateurs sur la création de valeur à long terme pour les actionnaires.

Formular 4 Zusammenfassung: Axogen, Inc. (AXGN) gab bekannt, dass Direktor William P. Burke am 19.06.2025 14.150 Restricted Stock Units (RSUs) als seine jährliche Vorstandsaktienvergütung erhielt, bewertet mit etwa 150.000 US-Dollar zum Zeitpunkt der Gewährung. Die Transaktion ist mit „A“ (Erwerb) gekennzeichnet, was bestätigt, dass kein Handel am offenen Markt stattfand.

Jede RSU wandelt sich bei der Vesting am 19.06.2026, dem ersten Jahrestag der Gewährung, in eine Stammaktie um. Bis dahin bleibt die Zuteilung ein bedingtes Recht und keine ausstehende Aktie.

Nach der Zuteilung erhöhte sich Burkes derivative Beteiligung um 14.150 Einheiten, die alle direkt gehalten werden. Die Meldung verzeichnet keine Veräußerungen, Optionsausübungen oder Verkäufe und beeinflusst weder die Aktienanzahl noch die Liquidität des Unternehmens. Die Zuteilung entspricht der Vorstandsvergütungspolitik von Axogen und dient der Ausrichtung der Vergütung an langfristigem Aktionärswert.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Burke William P. Mr.

(Last) (First) (Middle)
C/O AXOGEN, INC. 13631 PROGRESS BLVD.
SUITE 400

(Street)
ALACHUA FL 32615

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Axogen, Inc. [ AXGN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/19/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) 06/19/2025 A 14,150 (2) (2) Common Stock 14,150 $0 14,150 D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
2. Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.
Remarks:
/s/ Marc Began, as attorney-in-fact for William Burke 06/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did AXGN disclose in the latest Form 4?

Director William P. Burke was granted 14,150 RSUs valued at about $150 k on 06/19/2025.

How many shares does each RSU represent?

Each RSU converts into one share of Axogen common stock upon vesting.

When will the RSUs granted to William Burke vest?

The award vests in full on 06/19/2026, one year after the grant date.

Were any AXGN shares sold or disposed of in this filing?

No. The filing shows only an acquisition of RSUs; there were no sales or dispositions.

What is the implied dollar value of the RSU grant?

Axogen valued the grant at $150,000 on the grant date.
Axogen Inc

NASDAQ:AXGN

AXGN Rankings

AXGN Latest News

AXGN Latest SEC Filings

AXGN Stock Data

748.16M
43.86M
4.79%
87.52%
8.91%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
ALACHUA